Cell Genesys GVAX Prostate Cancer Vaccine Will Begin Phase III Under Special Protocol Assessment

Clinical trial program will attempt to demonstrate superiority over taxane chemotherapy in treating hormone-refractory metastatic prostate cancer patients. Cell Genesys hopes to highlight tolerability, dosing convenience of vaccine if approved.